The WHO has published A72/A/CONF./2, for Agenda item 11.7. The date of the document is 23 May 2019, but it is the end of day negotiating text from Wed, May 22. The title is: Improving the transparency of markets for… Continue Reading
Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- and gene-therapies and… Continue Reading
Politico has published a copy of the new draft of the World Health Assembly (WHA) transparency resolution. WHA-Resolution_DRAFT_20-05-2019 The Politico account cites the disclosure of clinical trial costs as one area for transparency that is strongly opposed by some governments,… Continue Reading
At the May 7 informal, countries from Northern Europe with strong pharma industry lobbies proposed dozens of changes in the transparency resolution to make it weaker and in many cases confusing and meaningless. This table compares the two texts: Dif-April29-May7-WHA-Transparency-Resolution… Continue Reading
On Agenda item 11.7 – Access to medicines and vaccines, KEI offers the following comments on the transparency resolution. 1. Transparency should not be controversial. Policy makers and the public need to have better evidence in order to support policies… Continue Reading
KEI was one of 13 groups to support Public.Resource.Org in this important litigation over the ability of state governments to “leverage copyright to raise access barriers to important sources of legal information.” Charles Duan for the R-Street Institute is the… Continue Reading
KEI Advisory on NIST Green Paper RE: Publication of NIST Green Paper on Innovation and Federally-funded R&D Date: Expected Release by NIST on Weds, April 24, 2019 Background On Wednesday, April 24, 2019, The National Institute of Standards and Technology… Continue Reading
On April 19, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading
KEI intervention at SCCR 38, on copyright limitations and exceptions April 3, 2019 KEI suggests the WIPO SCCR increase its ambitions on access to knowledge, making it more political, and while more challenging, more worth the investment of time and… Continue Reading
The following was sent to US DOJ today, to express KEI’s opposition to the IBM acquisition of Red Hat. 13 March 2019 Bindi R. Bhagat U.S. Department of Justice Antitrust Division Technology and Financial Services Section Dear Ms. Bhagat, Thank… Continue Reading